HEALTH TECHNOLOGY

TribeHealth Selects Engooden Health to Transform Care Delivery Through Chronic Disease Management

Engooden | August 26, 2022 | Read time : 03:00 min

TribeHealth Selects

Engooden Health, a company redefining chronic disease management announced a partnership with TribeHealth, a strategic care management organization. The collaboration enables TribeHealth to offer its partners and their patients chronic disease management services through Engooden’s scalable, technology-enhanced solution.

TribeHealth partners with health systems to serve as both a trusted advisor and tactical partner to help increase revenue, improve quality of care, and enhance the patient experience. A leader in working to achieve health equity and improve access to care, TribeHealth offers insights into patient populations and specific programs that best support those populations.

“At TribeHealth, we are committed to transforming care delivery for the betterment of our healthcare system and all patients, and Engooden is equally committed to this cause,” said Lyndsey Lord, Co-founder and COO of TribeHealth. “Engooden has a proven and effective, trust-based model for helping patients manage their chronic conditions with the expertise of their care navigators. We want to help connect as many people as possible to these resources at the appropriate time.”

Engooden’s chronic disease management platform is a proven, scalable solution for providers, health systems, and payers. Their proprietary technology automatically surfaces actionable insights to its care navigators, allowing them to intervene with the right patients at the right time. Care navigators help bridge care gaps for tens of thousands of patients through consistent, trust-based engagement. The personalized service is popular with patients, with an 88% annual program retention rate.

Engooden Health partners with healthcare organizations of all types and sizes, bringing critical chronic disease management services to everyone from traditional fee-for-service physicians to accountable care organizations federally qualified health centers (FQHC), rural health clinics and other value-based care organizations.

Engooden’s tech-enhanced chronic disease management services allow us to build trust with patients at scale, driving clinical and financial outcomes that can help organizations better perform in value-based care. This partnership combines our shared commitment to health equity and desire to transform healthcare delivery. Together, we can help organizations to provide more comprehensive, high-quality care.”

Ryan Atwood, VP of Payer Relations and Regulatory Compliance at Engooden Health

More than 133 million Americans are currently managing chronic diseases, many of whom would benefit greatly from this historically underutilized service. In an effort to increase utilization, Centers for Medicare & Medicaid Services recently increased reimbursement for chronic care management services, further validating the role CCM plays in improving patient health and quality of life while driving down costs across the healthcare spectrum from fee-for-service to risk-based programs. Chronic disease management services include education, coaching, and advocacy. Common patient success stories include results such as reduced HbA1c, weight loss, decreased blood pressure, mitigating symptoms of depression, and much more. TribeHealth and Engooden are partnering to immediately make this service more readily available to all patients who need it.

About TribeHealth
TribeHealth designs networks of people and technology to assist patients, providers, and payers achieve optimal health & cost outcomes. TribeHealth partners with leading healthcare organizations to support new and existing care delivery models while assisting with preventive engagement strategies aimed at successful population care. TribeHealth was formed in 2020 by a team of clinicians and health scientists to bring responsive care resources to as many people as possible. 

About Engooden Health
Engooden Health is the only company to offer scalable chronic care management (CCM) services and technology for physicians, health systems, and payers to identify rising-risk and chronically ill patients and positively impact their health trajectories. Through technology-driven, personalized intervention by experienced and empathetic care navigators, Engooden connects with thousands of patients each month, addressing their barriers to care while helping its customers effectively manage population health and value-based care programs. Founded in 2016, Engooden Health is headquartered in Boston. 

Spotlight

As patients with high deductible health plans (HDHPs) shoulder more of the burden for payments, you should expect those costs to rise, especially since collecting payments from patients costs three to four times more than collecting from payers. Its time to take a different approach to patient billing, one that recognizes patients are not insurers, but rather customers-who often have financial challenges and who rarely possess a firm knowledge of industry practices and jargon.

Spotlight

As patients with high deductible health plans (HDHPs) shoulder more of the burden for payments, you should expect those costs to rise, especially since collecting payments from patients costs three to four times more than collecting from payers. Its time to take a different approach to patient billing, one that recognizes patients are not insurers, but rather customers-who often have financial challenges and who rarely possess a firm knowledge of industry practices and jargon.

Related News

HEALTH TECHNOLOGY

Redox and Intelligent Medical Objects Partnering to Augment Healthcare Data

Redox Inc. | October 18, 2022

Redox, the company setting the stage for composable healthcare, has partnered with Intelligent Medical Objects, a healthcare data enablement company to standardize clinical data from diverse systems into consistent, structured, clinically validated terminology including comprehensive mapping to major global coding systems. Now healthcare companies can spend more time building improved patient and clinician experiences by eliminating the lengthy and taxing process of combining multiple point solutions. This announcement comes directly after last week's launch of API Actions, a modular way for healthcare companies to build out their ideal workflows. This present partnership between IMO and Redox benefits any healthcare company that receives clinical problem or diagnosis data from multiple organizations. As a result, these are further able to enrich healthcare data using consistent terminology across all data standards, formats, and workflows with a single Redox API. "Redox is dedicated to making sure that healthcare data can empower builders to create new experiences for patients and providers. We want to be clear that composable healthcare is a practice of bringing together the best technologies to produce the best solutions, and we're glad to be doing so with IMO." Redox CEO Luke Bonney "Clinical patient data is a powerful resource in healthcare. IMO partnering with Redox will accelerate the ability for healthcare companies to leverage that data to create better outcomes for doctors and patients," said IMO CEO Ann Barnes. Redox will leverage IMO's technology to standardize healthcare data for its customers. Using IMO Precision Normalize will allow Redox to accelerate data normalization for its hospital and software vendor clients. This lets healthcare technology companies spend more time building powerful solutions by eliminating the lengthy and costly process of cleaning and standardizing messy clinical data. SNOMED® is a registered trademark of International Health Terminology Standards Development Organisation About Redox Payers, providers, digital health companies, and other healthcare entities use Redox to produce differentiated experiences for patients and clinicians. Connecting to more than 30,000 healthcare organizations, Redox provides a composable software experience across the healthcare ecosystem. With our single API, product teams are empowered to build whatever they can imagine. Redox accelerates innovations that make healthcare data more useful than ever before. About IMO Intelligent Medical Objects is a healthcare data enablement company. From clinical documentation at the point of care to complex approaches to population health management, IMO ensures clinical data integrity and quality—making patient information fit-for-purpose across the healthcare ecosystem. For almost three decades, IMO's footprint in EHRs—across more than 4,500 US hospitals—powers our expert ability to capture and preserve clinical intent wherever and however data is used. Our primary clients span individual doctors and physician groups, hospitals and clinics, large integrated delivery networks, inpatient ORs and surgical centers, global electronic health record providers, health information exchanges, clinical data registries, payers, life sciences companies, and healthcare analytics vendors.

Read More

HEALTHTECH SECURITY

BeeKeeperAI Applies Sightless Computing Technology to Pediatric Rare Disease Project

BeeKeeperAI and Novartis Biome | October 20, 2022

BeeKeeperAI, the pioneer in sightless computing on protected data, announced that it worked with scientists from Novartis Biome’s Evidence Lab and the University of California, San Francisco to train and validate an algorithm to predict instances of a rare childhood condition using real patient data from health records. This project marks the first time that confidential computing technology has been leveraged to support sightless computation by an algorithm against protected health information. “This project is an important milestone in the development of the rare disease solution by the Evidence Lab,” said Robin Roberts, Co-founder and Chief Operating Officer at Novartis Biome. “Rare diseases are often challenging to diagnose and if left untreated, they can significantly diminish a patient’s quality of life. With BeeKeeperAI, our scientists were able to securely access a large gold standard dataset that enabled us to improve the predictive capabilities of our algorithm, bringing us much closer to identifying patients early in the disease course and to improving their outcomes.” The Novartis Biome Evidence Lab was developed in collaboration with health systems and data providers as a space for health tech companies to test their digital solutions and identify ways to optimize and scale their offerings. BeeKeeperAI’s zero trust architecture supports sightless computing of algorithms against protected information. It uses advanced encryption within secure computing enclaves to enable data stewards and algorithm developers to collaborate without exposing the data or revealing important IP. The platform eliminates reliance on data deidentification or difficult to enforce contractual agreements that typically govern access to protected health information. “The traditional mechanisms for securing permission to use confidential patient information to develop healthcare AI are time-consuming and costly and that has slowed the pace of innovation in the field. We developed our platform with an eye towards addressing the constraints of existing approaches for accessing protected information and helping algorithm developers and data stewards collaborate far more effectively,” Michael Blum, MD, Co-founder and Chief Executive Officer at BeeKeeperAI The Novartis project leveraged Microsoft Azure’s confidential computing environment utilizing an Intel SGX secure enclave. Prior to moving the data into the secure enclave at UCSF, BeeKeeperAI worked with clinical and data science experts at UCSF to curate, harmonize, and encrypt data that included 28 pediatric patients diagnosed with the pediatric rare disease in question and an additional 2,000 matched controls. Simultaneously, BeeKeeperAI enabled the Novartis scientists to prepare the algorithm for the secure environment, including encrypting and uploading it to the BeeKeeperAI cloud platform. Encrypting both the data and the algorithm ensured that they remain protected throughout the computing process. Once the encrypted algorithm and data were in the secure enclave, they were decrypted, and the algorithm was allowed to compute against the identifiable data. The process was fully automated and sightless. The output of the computation was a report that provided performance metrics. Novartis scientists used the feedback from the BeeKeeperAI platform to fine-tune the algorithm and rerun it against the data. Through this iterative loop, they significantly improved the predictive capabilities of their solution to detect patients with the rare condition. The solution is now ready for further validation at additional academic medical centers known for treating this rare condition. BeeKeeperAI will be participating in the Novartis Biome's "Closing the Digital Divide: Validation through Partnership" event on Wednesday, October 19, where they will share more details of the healthcare AI project with Novartis Biome and UCSF. About Novartis Biome Novartis Biome is a bridge to help partners become an extension of Novartis own teams, working with them as easily and productively as possible to jointly innovate and co-develop digital solutions at scale. The Biome is committed to partnering with the best in the ecosystem to combine deep scientific experience with the expertise of the tech world to develop – and crucially – scale digital solutions that improve and extend patients’ lives. About BeeKeeperAI BeeKeeperAI is the pioneer in confidential, sightless computing within a zero-trust architecture for the development and deployment of AI in healthcare and other privacy protected data. BeeKeeperAI is accelerating the broader availability of AI-powered solutions that will help to redefine the future of healthcare and commerce.

Read More

HEALTH TECHNOLOGY

IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation

IQVIA | September 29, 2022

IQVIA a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation. TRUSTArc’s third-party validation demonstrates that IQVIA’s DCT program processes personal data in accordance with GDPR, allowing customers to address participant and investigator privacy concerns that may arise because of their participation in decentralized trials. “At IQVIA, we are committed to delivering decentralized studies, we recognize the criticality of patient data protection in doing this and we understand the focus on data protection by European regulators,” said Ronan Brown, SVP and head of Patient Centric Solutions & Decentralized Trials. “IQVIA is proud to have this validation prove our longstanding dedication to data protection in decentralized trials.” TRUSTArc maps it’s GDPR Validation requirements to applicable GDPR Articles and ISO 27001 standards, alongside the standards of it’s own Privacy and Data Governance Accountability Framework. This validation is yet another step IQVIA has taken to enable DCTs to be brought to a wider group of participants, improving diversity, sustainability, and trust in clinical development. “Achieving a GDPR validation demonstrates IQVIA’s commitment to ensuring the highest standards of delivering decentralized studies to the people it serves. Organizations of all sizes must become privacy-forward to earn the trust of their customers. IQVIA has consistently prioritized being privacy-forward to earn the trust of their customers and the TRUSTArc GDPR and CCPA Validations reinforce that standing.” Chris Babel, CEO, TRUSTArc About IQVIA IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures.

Read More